Autolus Therapeutics plc American Depositary Share (AUTL)
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
- Headquarters
- United States
- Employees
- 752
- Market Cap
- $540M
About Autolus Therapeutics plc American Depositary Share
Autolus Therapeutics PLC is a biopharmaceutical company developing next-generation programmed T-cell therapies for the treatment of cancer. The company's clinical-stage pipeline comprises Obe-cel (obecabtagene autoleucel), AUTO1/22, AUTO3, AUTO5, AUTO6, AUTO7 & AUTO8. Company's T cell programming technologies tailors therapies to address the specific disease targeting and introduce new programming modules into a patient's T cells to give those T cells improved properties to recognize target cells and overcome fundamental disease defense mechanisms.
SentiSense also tracks daily options readings for Autolus Therapeutics plc American Depositary Share: IV rank, put/call percentile, 25-delta skew, open-interest walls, and unusually active contracts, each measured against the stock's own history. Sign in to view them.
Autolus Therapeutics plc American Depositary Share stock analysis, sentiment tracking, and market intelligence on SentiSense.